ArticleBMJ open diabetes research & care2021

Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease.

Odette S Reifsnider et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.